Video
Video
03/31/2024
Jeffrey A. Sparks, MD, MMSc
In this video, Jeffrey A. Sparks, MD, MMSc, discusses his study that evaluated the outcomes of patients with pre-existing rheumatoid arthritis (RA) who initiated immune checkpoint inhibitors for cancer, if...
03/31/2024
Video
Video
03/31/2024
Jeffrey A. Sparks, MD, MMSc
In this video, Jeffrey A. Sparks, MD, MMSc, discusses his study that evaluated the outcomes of patients with pre-existing rheumatoid arthritis (RA) who initiated immune checkpoint inhibitors for cancer, if...
03/31/2024
Video
Video
03/31/2024
Jeffrey A. Sparks, MD, MMSc
In this video, Jeffrey A. Sparks, MD, MMSc, discusses his study that evaluated the outcomes of patients with pre-existing rheumatoid arthritis (RA) who initiated immune checkpoint inhibitors for cancer, if...
03/31/2024
Video
Video
03/31/2024
Jeffrey A. Sparks, MD, MMSc
In this video, Jeffrey A. Sparks, MD, MMSc, discusses his study that evaluated the outcomes of patients with pre-existing rheumatoid arthritis (RA) who initiated immune checkpoint inhibitors for cancer, if...
03/31/2024
Video
Video
03/25/2024
Brenden P. Lucy, MD
In a small clinical trial, researchers found that patients taking suvorexant, an FDA-approved treatment for insomnia, had reduced levels of amyloid beta (amyloid-β) and tau phosphorylation proteins, which...
03/25/2024
Video
Video
03/25/2024
Brenden P. Lucy, MD
In a small clinical trial, researchers found that patients taking suvorexant, an FDA-approved treatment for insomnia, had reduced levels of amyloid beta (amyloid-β) and tau phosphorylation proteins, which...
03/25/2024
Video
Video
03/25/2024
Brenden P. Lucy, MD
In a small clinical trial, researchers found that patients taking suvorexant, an FDA-approved treatment for insomnia, had reduced levels of amyloid beta (amyloid-β) and tau phosphorylation proteins, which...
03/25/2024
Video
Video
03/25/2024
Brenden P. Lucy, MD
In a small clinical trial, researchers found that patients taking suvorexant, an FDA-approved treatment for insomnia, had reduced levels of amyloid beta (amyloid-β) and tau phosphorylation proteins, which...
03/25/2024
Video
Video
03/25/2024
Brenden P. Lucy, MD
In a small clinical trial, researchers found that patients taking suvorexant, an FDA-approved treatment for insomnia, had reduced levels of amyloid beta (amyloid-β) and tau phosphorylation proteins, which...
03/25/2024
Video
Video
03/25/2024
Brenden P. Lucy, MD
In a small clinical trial, researchers found that patients taking suvorexant, an FDA-approved treatment for insomnia, had reduced levels of amyloid beta (amyloid-β) and tau phosphorylation proteins, which...
03/25/2024